NASDAQ$CYRX

CryoPort Inc. · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Cryoport experienced macroeconomic headwinds during Q3 2022, impacting revenue despite growth in key areas like Cryoport Systems and clinical trial support.

Cryoport's Q3 2022 revenue increased by 7% year-over-year to $60.5 million, but was impacted by macroeconomic headwinds. The company is revising its full-year 2022 revenue guidance to $232-$238 million. Despite these challenges, Cryoport saw growth in key areas and is optimistic about future growth with new products and services launching in 2023.

  • Total revenue for Q3 2022 was $60.5 million, a 7% increase compared to Q3 2021.
  • Gross margin for Q3 2022 was 43.7%, up from 41.5% in Q3 2021.
  • The company supported nine commercial therapies and 643 global clinical trials as of September 30, 2022.
  • Revised full-year 2022 revenue guidance is $232 million to $238 million.

Headline financials

Total Revenue

$60.5M

Previous: $56.7M+6.7%
EPS (adj)

-$0.15

Previous: -$0.18+16.7%
Adjusted EBITDA

$4.7M

No prior period
Capital Expenditures

-$14.3M

Previous: -$15.6M+8.4%
Free Cash Flow

-$19.6M

Previous: -$22.1M+11.4%
Net Income

-$5.32M

Previous: -$6.53M+18.5%
Operating Income

-$7.8M

Previous: -$4.58M-70.5%
Gross Profit

$26.4M

Previous: $23.5M+12.4%
Cash & Equivalents

$30.7M

Previous: $43.7M-29.7%
Total Assets

$1.03B

Previous: $824M+25.4%
Stock-Based Comp

$5.37M

Previous: $4.15M+29.4%

Revenue & EPS history

CryoPort · Revenue · Quarterly

$60.5M

Q3 2022+6.7%vs Q3 2021
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Forward guidance

The Company’s revised revenue guidance for the full year 2022 is $232 - $238 million, and will be driven primarily by the growth from our support of global clinical trials and commercially launched therapies from our cell and gene therapy clients; growth in temperature-controlled logistics for the life sciences industry; and demand for our cryogenic systems solutions.

Tailwinds

  • Growth from support of global clinical trials.
  • Growth from commercially launched therapies from cell and gene therapy clients.
  • Growth in temperature-controlled logistics for the life sciences industry.
  • Demand for cryogenic systems solutions.

Headwinds

  • Ongoing and prolonged COVID-19 pandemic and related shut downs globally.
  • Supply chain constraints.
  • Inflationary pressures.
  • Economic uncertainty.
  • Effects of foreign currency fluctuations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+2.2%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+8.5%

Avg return

30 days after

49%

28 / 57 earnings

Positive

+31.6%

Q4 2013

Best reaction

-33.8%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+19.4%+33.2%+58.2%
Q4 2025+2.9%-4.7%+3.3%
Q3 2025-8.2%-7.4%+3.5%
Q1 2025+23.4%+23.3%+23.7%
Q4 2024+30.6%-7.1%+5.7%
Q3 2024-3.6%-0.9%-8.6%
Q2 2024+3.9%+10.0%+9.8%
Q1 2024-17.5%-16.7%-30.6%
Q4 2023-12.3%-7.3%+10.3%
Q3 2023+8.9%+8.4%+46.7%
Q2 2023-0.2%+1.2%-5.0%
Q1 2023+13.9%+4.5%-6.3%
Q4 2022+13.7%+9.9%+15.3%
Q3 2022-33.8%-35.7%-26.5%
Q2 2022+6.8%+5.2%-16.1%
Q1 2022-8.5%-14.6%-2.8%
Q4 2021+9.3%+7.0%+1.9%
Q3 2021-1.0%-1.2%-22.8%
Q2 2021-1.5%-3.6%+2.9%
Q1 2021+9.0%+11.6%-2.4%
Q4 2020-0.7%-11.7%-12.5%
Q3 2020+5.0%+24.2%+12.8%
Q2 2020-2.0%-5.0%+55.5%
Q1 2020+2.0%+17.0%+22.6%
Q4 2019+2.1%+0.8%-11.9%
Q3 2019+1.4%+3.9%+5.6%
Q2 2019+19.7%+24.5%+2.3%
Q1 2019+12.5%+12.5%+17.7%
Q4 2018-0.6%+6.6%+22.3%
Q3 2018-1.0%-9.4%-2.0%
Q2 2018-1.6%-14.7%-6.5%
Q1 2018+11.8%+23.0%+67.4%
Q4 2017+3.8%+6.4%-7.0%
Q3 2017-15.1%-22.9%-10.5%
Q2 2017-2.0%+3.6%+28.6%
Q1 2017+8.2%+9.0%+46.9%
Q4 2016+23.7%+9.0%+23.7%
Q2 2016-7.5%
Q1 2016+10.2%
Q4 2015-3.0%
Q3 2015+7.5%
Q2 2015-14.4%
Q1 2015-2.2%
Q4 2014+6.4%
Q3 2014-5.6%
Q4 2013+31.6%
Q3 2013-8.0%
Q2 2013+5.3%
Q1 2013+0.0%
Q4 2012-3.1%
Q3 2012-10.8%
Q2 2012-8.0%
Q1 2012-2.7%
Q1 2010+11.2%
Q3 2009+1.4%
Q2 2009-2.8%
Q1 2009+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro